Quantification of Inflammation Following Nd:YAG Laser Capsulotomy and Assessing the Anti-inflammatory Effects of Nepafenac 0.1% and Betamethasone 0.1%. (17th February 2021)

• Record Type: Journal Article
• Authors: Jinagal, Jitender; Sahu, Sabin; Gupta, Gaurav; Khurana, Surbhi; Gupta, Rohit; Gupta, Parul Chawla; Ram, Jagat
• Is Part Of: Ocular immunology and inflammation. Volume 29:Number 2(2021)
• Page Start: 411
• Page End: 416
• Publication Date: 2021-02-17
• Subjects: Cataract surgery -- laser flare photometry -- posterior capsular opacification -- YAG cap -- YAG capsulotomy; Eye -- Diseases -- Immunological aspects -- Periodicals; Eye -- Inflammation -- Periodicals; 617.7
• DOI: 10.1080/09273948.2019.1668025
• Languages: English
• ISSNs: 0927-3948

Abstract

ABSTRACT: Purpose : To quantify the intraocular inflammation, measured using laser flare photometry (LFP), after Nd:YAG capsulotomy and compare the effects of different topical anti-inflammatory regimes. Methods : A single-center, prospective, randomized controlled study, which included 90 eyes of 90 patients with visually significant posterior capsular opacification. In all patients, Nd:YAG capsulotomy was done and was then randomized into three groups: (A) Topical betamethasone 0.1%; (B) Topical nepafenac 0.1%; and (C) Control group: did not receive any anti-inflammatory agent post capsulotomy. Results : There was a significant increase in the mean LFP values 2 h following laser capsulotomy ( p < 0.001) and then declined gradually and came back to pre-laser values by 2 weeks in all three groups. The mean LFP values, central macular thickness, and best corrected visual acuity were comparable among groups. None developed central macular edema. Conclusion : Intraocular inflammation following Nd:YAG capsulotomies is minimal and transient. Routine use of prophylactic anti-inflammatory agents may be avoided.